NO750246L

NO750246L -

Info

Publication number: NO750246L
Application number: NO750246A
Authority: NO
Inventors: Hector Chabin Simon
Original assignee: Hector Chabin Simon
Priority date: 1974-08-08
Filing date: 1975-01-28
Publication date: 1976-02-10
Also published as: IN142315B; CA1026672A; AU7829775A; DOP1975002269A; GB1475651A; JPS5126210A; NL184665B; DE2508338A1; PH12112A; IL46517A0; NL7503371A; FR2281103B1; DE2508338C2; NL184665C; IT1056277B; IL46517A; FR2281103A1; LU71933A1

Description

Foreliggende oppfinnelse angår et farmasøytisk preparat for behandling av cancer og en fremgangsmåte for å inhibere veksten av cancer i mennesker. The present invention relates to a pharmaceutical preparation for the treatment of cancer and a method for inhibiting the growth of cancer in humans.

Cancer defineres i alminnelighet som en abnorm og ukontrollert ny vekst i celler og vev som frembringer uheldige virkninger i mennesker og som ofte er dødelig. Når således celler og vev uten noen forklarlig grunn vokser hurtigere enn normalt og utvikler abnormale former og størrelser og opphører å virke på normalt vis, sies de å være angrepet av kreft. Cancer is generally defined as an abnormal and uncontrolled new growth in cells and tissues that produces adverse effects in humans and is often fatal. Thus, when cells and tissues for no apparent reason grow faster than normal and develop abnormal shapes and sizes and cease to function in a normal way, they are said to be attacked by cancer.

Mange typer av cancer kan diagnostiseres. Eksempelvis■er minst 50% av alle cancere synlige ved undersøkelse, og minst ytterligere 25% kan påvises ved spesielle undersøkelsesinstrumenter som kan innføres i legemsåpninger„ Mange cancere har gjenkjennelige symptomer. Many types of cancer can be diagnosed. For example, at least 50% of all cancers are visible on examination, and at least a further 25% can be detected by special examination instruments that can be inserted into body openings. Many cancers have recognizable symptoms.

Urinveiscancer frembringer f.eks. et begynnelsessymptom på hema.turia, dvs. blod i urinen, og sykdommen ledsages vanligvis av hyppig urinering og smerte. Beliggenheten av canceren kan bestemmes ved røntgen- og cystoskopisk inspeksjon av selve urinblæren,og dens behandling kan derfor følges. Urinary tract cancer produces e.g. an initial symptom of hema.turia, i.e. blood in the urine, and the disease is usually accompanied by frequent urination and pain. The location of the cancer can be determined by X-ray and cystoscopic inspection of the bladder itself, and its treatment can therefore be followed.

Lungecancer har øket i hyppighet i de'siste 10. eller 15 år.Lung cancer has increased in frequency in the last 10 or 15 years.

Den følges vanligvis av begynnelsen av en vedholdende hoste som ikke synes alvorlig til å begynne med før blod viser seg i opphostet slim. It is usually followed by the onset of a persistent cough that does not seem serious at first until blood appears in the expectorated mucus.

Forskjellige former for cancer kan være svekkende og kan ledsages av tap av appetitt, vekttap, forandringer i humør, forandringer i hudtone og andre merkbare symptomer. Different forms of cancer can be debilitating and can be accompanied by loss of appetite, weight loss, changes in mood, changes in skin tone and other noticeable symptoms.

Skjønt det innsees at cancerterapi-feltet har vært underkastet en intens forskning og studium i de senere år i løpet av hvilke en stor del av studiet har vært rettet på kjemoterapi, har der vært funnet meget få virksomme stoffer for lindring av tilstanden. Although it is recognized that the field of cancer therapy has been subject to intense research and study in recent years, during which a large part of the study has been directed at chemotherapy, very few effective substances have been found to alleviate the condition.

Man har nu oppdaget et farmasøytisk preparat som er effektivt for behandling av mange typer av cancer ved å administrere preparatet til en cancerbærende vert, som mennesker„ A pharmaceutical preparation has now been discovered which is effective for the treatment of many types of cancer by administering the preparation to a cancer-bearing host, such as humans.

Det er således et mål ved oppfinnelsen å fremskaffe en metodeIt is thus an aim of the invention to provide a method

og et farmasøytisk preparat for anvendelse ved behandling av cancer. and a pharmaceutical preparation for use in the treatment of cancer.

Generelt sagt består foreliggende oppfinnelse i en fremgangsmåte og et farmasøytisk preparat for denne, for anvendelse for å inhibere veksten av cancer i mennesker, omfattende en fysiologisk godtagbar oppløsning hvori er oppløst en liten, men effektiv mengde friedelan-3-on„ Uttrykket "friedelan-3-on" er her anvendt for å inn-befatte derivater derav med lignende egenskaper. Generally speaking, the present invention consists of a method and a pharmaceutical preparation for this, for use in inhibiting the growth of cancer in humans, comprising a physiologically acceptable solution in which a small but effective amount of friedelan-3-one is dissolved. 3-on" is used here to include derivatives thereof with similar properties.

Fortrinnsvis omfatter oppløsningen å oppløse den nevnte lille, men effektive mengde av friedelan-3-on i ethanol i vektmengder fra .0,01% til 0,4%. Denne oppløsning anvendes som en stamoppløsning fra hvilken doser fremstilles ved å tilsette en forutbestemt mengde av den nevnte oppløsning til vann tilstrekkelig til å muliggjøre oral inhtagelse av det fortynnede preparat av en pasient under behandling. Preferably, the dissolution comprises dissolving said small but effective amount of friedelan-3-one in ethanol in amounts from 0.01% to 0.4% by weight. This solution is used as a stock solution from which doses are prepared by adding a predetermined amount of said solution to water sufficient to enable oral ingestion of the diluted preparation by a patient under treatment.

Dosemengdene kan variere fra 1 til ca. 15 dråper av den før-nevnte oppløsning tilsatt til vann for å taes av en pasient minst før hvert måltid på en daglig basis under legetilsyn. Det foretrukne stampreparat er et som inneholder 0,04% friedelan-3-on oppløst i ethanol. The dose amounts can vary from 1 to approx. 15 drops of the aforementioned solution added to water to be taken by a patient at least before each meal on a daily basis under medical supervision. The preferred stock preparation is one containing 0.04% friedelan-3-one dissolved in ethanol.

Virkningen av den foregående droge kan ytterligere biståes ved tilsetning av hjelpestoffer, f .eks. klorofyll og en fenolisk harpiks., Det farmasøytiske preparat kan således omfatte på vektbasis 0,01 - 0,4% f riedelan-3-on, 0,006%- 0,12% klorofyll og 0,6 - 3,7% av clen nevnte fenoliske harpiks oppløst i ethanol. Det synes som om hjelpe-stoffene bidrar til å motvirke odører som er typiske for visse cancere. Hva deres virkning enn er, har disse hjelpestoffer vist seg å være temmelig nyttige når de kombineres med oppløsningen inneholdende friedelan-3-on. The effect of the preceding drug can be further assisted by the addition of excipients, e.g. chlorophyll and a phenolic resin., The pharmaceutical preparation can thus comprise on a weight basis 0.01 - 0.4% of friedelan-3-one, 0.006% - 0.12% chlorophyll and 0.6 - 3.7% of the clen mentioned phenolic resins dissolved in ethanol. It seems that the auxiliary substances help to counteract odors that are typical of certain cancers. Whatever their action, these excipients have been found to be quite useful when combined with the solution containing friedelan-3-one.

Et foretrukket stampreparat er et som inneholder 0,04% frxedelan-3-on, 0,015% klorofyll og 1,65% av den nevnte fenoliske harpiks opp-løst i ethanol. Doser av dette preparat kan fremstilles som beskrevet ovenfor. A preferred stock preparation is one containing 0.04% frxedelan-3-one, 0.015% chlorophyll and 1.65% of the aforementioned phenolic resin dissolved in ethanol. Doses of this preparation can be prepared as described above.

Skjønt de foreslåtte doser er meget fortynnet, kan en svak toksisk bireaksjon forekomme når det foregående preparat administreres oralt til en pasient. Slike bireaksjoner kan være kjennetegnet av en gradvis stigning i temperatur ledsaget av en svak hodepine og milde smerter i visse ledd. Slik hodepine og/eller smerter kan behandles med "aspirin" eller andre velkjente hodepinemidler. Disse bireaksjoner er milde. Although the suggested doses are very diluted, a mild toxic side reaction may occur when the preceding preparation is administered orally to a patient. Such side effects may be characterized by a gradual increase in temperature accompanied by a slight headache and mild pain in certain joints. Such headaches and/or pain can be treated with "aspirin" or other well-known headache remedies. These side effects are mild.

Skjønt bestanddelene som anvendes i de farmasøytiske preparater kan sammensettes i .forskjellige forhold, har forsøk vist at det følgende preparat er særlig foretrukket når det oppløses i 100 .ml ethanol eller dets ekvivalent: (1) friedelan-3-on 0,0333 g klorofyll O,0l66 g Although the ingredients used in the pharmaceutical preparations can be composed in different proportions, experiments have shown that the following preparation is particularly preferred when dissolved in 100 ml of ethanol or its equivalent: (1) friedelan-3-one 0.0333 g chlorophyll O.0l66 g

fenolisk harpiks' 1,3326 gphenolic resin' 1.3326 g

Ethanol har en tetthet på 0,785 g/ml, og 100 ml veier derfor 78,5 Q-Når således det foregående preparat fremstilles under anvendelse av 100 ml ethanol som oppløsningsmiddel, er totalvekten av oppløsningen 79,99- hvilket svarer til følgende tilnærmede sammensetning beregnet i vekt%: Ethanol has a density of 0.785 g/ml, and 100 ml therefore weighs 78.5 Q-When the previous preparation is thus prepared using 100 ml of ethanol as solvent, the total weight of the solution is 79.99- which corresponds to the following approximate composition calculated in % by weight:

(2) friedelan-3-on 0,04%(2) friedelan-3-one 0.04%

klorofyll 0,02%chlorophyll 0.02%

fenolisk harpiks 1,65%phenolic resin 1.65%

Som angitt ovenfor, kan preparatet i ethanol variere i vekt som følger: As indicated above, the preparation in ethanol may vary in weight as follows:

(3) friedelan-3-on 0,01% til 0,4%(3) friedelan-3-one 0.01% to 0.4%

klorofyll 0,006% til 0,12%chlorophyll 0.006% to 0.12%

fenolisk harpiks 0,6% til 3,7%phenolic resin 0.6% to 3.7%

Skjønt ethanol foretrekkes som det fysiologiske eller farmasøytisk godtagbare oppløsningsmiddel, kan andre oppløsningsmidler for oral inntagelse av pasienten anvendes. Although ethanol is preferred as the physiologically or pharmaceutically acceptable solvent, other solvents for oral ingestion by the patient may be used.

Blandingen av bestanddelene av preparatet (1) utføres ved å tilsette 0,333 g friedelan-3-on, 0,0166 g klorofyll og 1,3326 g fenolisk: harpiks til 100 ml ethanol ved omtrent værelsetemperatur, idet bestanddelene oppløses ved moderat omrøring for å danne preparatet (2) ovenfor. The mixing of the components of the preparation (1) is carried out by adding 0.333 g of friedelan-3-one, 0.0166 g of chlorophyll and 1.3326 g of phenolic: resin to 100 ml of ethanol at about room temperature, the components dissolving with moderate stirring to form the preparation (2) above.

Det foregående foretrukne preparat anvendes under legetilsyn i foreskrevne dosemengder.Dosen kan variere efter pasientens alder og i henhold til de iakttagelser som er gjort av den behandlende lege. Dette vil fremgå fra de følgende sykehistorier som innbefatter pasi-enter av forskjellig alder. The preceding preferred preparation is used under medical supervision in prescribed doses. The dose may vary according to the patient's age and according to the observations made by the attending physician. This will be evident from the following case histories, which include patients of different ages.

Pasient APatient A

En 35 år gammel pasient (kvinne) ble av legen diagnostisert tilA 35-year-old patient (woman) was diagnosed by the doctor as

å ha cancer i urinblæren hvor ca. 75% av blæren var angrepet av cancer. Den emosjonelle tilstand hos pasienten før behandling var lav, hun var apatisk og svekket og viste tap av appetitt. Hun hadde vanskelig for å holde på urinen, hvilket ga seg utslag i hyppig urinering. having cancer in the urinary bladder where approx. 75% of the bladder was attacked by cancer. The emotional state of the patient before treatment was low, she was apathetic and weakened and showed a loss of appetite. She had difficulty holding in urine, which resulted in frequent urination.

Preparatet (1) angitt ovenfor, ble anvendt ved behandlingen som ble utført under tilsyn av en lege. Behandlingen omfattet oral inntagelse av en dose på 5 dråper av preparatet tilsatt til ca. 100 ml vann eller den mengde vann som lett kunne inntaes oralt av/,, pasienten. Dosen på 5 dråper i vann ble tatt 5 ganger daglig, en dose før hvert måltid, en dose ca. kl. 11.00 og en dose ca. kl. 17.00 i 7 uker. The preparation (1) stated above was used in the treatment which was carried out under the supervision of a doctor. The treatment included oral intake of a dose of 5 drops of the preparation added to approx. 100 ml of water or the amount of water that could easily be ingested orally by the patient. The dose of 5 drops in water was taken 5 times a day, one dose before each meal, one dose approx. at 11.00 and a dose approx. at 17.00 for 7 weeks.

Den behandlende lege merket en tydelig forbedring i pasienten som det fremgikk av øket appetitt og en vektøkning og også fremgikk av pasientens evne til å holde på urinen i blæren i over ca. 5 timer. Hennes følelse av svekkelse forsvant, og hennes hudtone forbedret seg. Pasienten er fremdeles under behandling, og hennes tilstand er tydelig lindret. The attending physician noted a clear improvement in the patient, as evidenced by increased appetite and weight gain and also by the patient's ability to hold urine in the bladder for over approx. 5 hours. Her sense of weakness disappeared and her skin tone improved. The patient is still undergoing treatment, and her condition has clearly improved.

Pasient BPatient B

Denne pasient (kvinne, alder 45 år) ble diagnostisert å ha brystcancer, idet brystet inneholdt en cancertumor og en benign tumor. Det ble anbefalt av legen at brystet skulle - fjernes, Huden av det angrepne område varkarakterisertav en følsom rødhet, hennes disposisjon var lav, og hun følte seg svekket og svak.• Hun ble brakt under en leges tilsyn, og den følgende dose av preparat (1) folé foreskrevet: 3 dråper tilsatt til ca. ioOral vann tatt 5 ganger daglig, en dose før hvert måltid, en dose ca. kl. 11.00 og en dose ca. kl. 17-00. This patient (female, age 45) was diagnosed with breast cancer, as the breast contained a cancerous tumor and a benign tumor. It was recommended by the doctor that the breast should - be removed, The skin of the affected area was characterized by a sensitive redness, her disposition was low, and she felt weakened and weak.• She was brought under the supervision of a doctor, and the following dose of preparation ( 1) foil prescribed: 3 drops added to approx. ioOral water taken 5 times a day, one dose before each meal, one dose approx. at 11.00 and a dose approx. at 17-00.

Efter en ukes behandling ble hun undersøkt av legen, og ingen klumper kunne iakttaes, hvilket ble tatt som en indikasjon på at tumorene var oppløst. Dette ble også bekreftet ved røntgenundersøk-else. Rødheten forsvant. Efter den første ukes dramatiske forbedring viste pasienten forbedret appetitt, følte seg sterkere, og hennes disposisjon var tydelig forbedret, og hudtonen var god. Forbedringen fortsatte fra den annen til den femte uke av behandlingen, men i et langsommere tempo. Behandlingene ble'avbrutt efter den femte uke, og pasienten ansees for å være frisk. After a week of treatment, she was examined by the doctor, and no lumps could be observed, which was taken as an indication that the tumors had dissolved. This was also confirmed by X-ray examination. The redness disappeared. After the first week's dramatic improvement, the patient showed improved appetite, felt stronger, her disposition was clearly improved, and her skin tone was good. Improvement continued from the second to the fifth week of treatment, but at a slower pace. The treatments were discontinued after the fifth week, and the patient is considered to be healthy.

Pasient CPatient C

En'64 år gammel mannlig pasient ble av legen diagnostisert å ha, cancer i en lunge. Tilfellet ble ansett, for å være uhelbredelig. A 64-year-old male patient was diagnosed by the doctor as having cancer in a lung. The case was considered to be incurable.

Han var blek, var apatisk, hadde en stadig vedvarende hoste, oppviste tap av appetitt, avtok i vekt og hans pusting var nedsatt. Preparat (1) ble foreskrevet som følger: 3 dråper tilsatt til ca. læ ml vann for oral inntagelse av pasienten fem ganger daglig, en dose før hvert måltid, en dose kl..11.00 og en dose kl. 17.00. Behandlingen ble fortsatt i lo uker. He was pale, apathetic, had a persistent cough, showed loss of appetite, was losing weight and his breathing was impaired. Preparation (1) was prescribed as follows: 3 drops added to approx. 1 ml of water for oral intake by the patient five times a day, one dose before each meal, one dose at 11.00 and one dose at 17.00. The treatment was continued for a few weeks.

Hostingen avtok efter den tredje dag, og pasientens ap<p>etittThe hosting decreased after the third day, and the patient's appetite

■-u■-u

forbedret seg. Efter 15 dagers behandling forbedret pasientens pusting seg. Behandlingen ble avsluttet efter 10 uker. Røntgen-analyse av lungen var negativ. Pasienten hadde en utmerket følelse av velvære, og er fremdeles under observasjon. improved. After 15 days of treatment, the patient's breathing improved. The treatment was terminated after 10 weeks. X-ray analysis of the lung was negative. The patient had an excellent sense of well-being and is still under observation.

P asient DPatient D

Nylig ble en ung mann på 19 år diagnostisert av en lege å ha leukemi. Han var apatisk, var meget svekket og oppviste tap av appetitt. Den følgende dosering av preparat (1) ble foreskrevet: Recently, a young man aged 19 was diagnosed by a doctor as having leukemia. He was apathetic, was very weak and showed loss of appetite. The following dosage of preparation (1) was prescribed:

en 3 dråpers dose i ca. 300 ml vann ble gitt oralt før frokost,a 3-drop dose for approx. 300 ml of water was given orally before breakfast,

2 dråper i vann før lunsj og 2 dråper i vann før middag. Denne dosering ble fortsatt daglig. 2 drops in water before lunch and 2 drops in water before dinner. This dosage was continued daily.

Efter tredje dags behandling var den unge manns appetitt tydelig forbedret. Han var i stand til å gå tilbake i arbeide og får fremdeles behandlingen. Han føler seg ikke lenger apatisk. Hans hudtone har forbedret seg. .Som det vil sees, ble en mindre dose anvendt ved behandling av den unge mann. Det foretrekkes at dosen bestemmes efter pasientens alder. Generelt, jo eldre personen er, desto større er dosen. Dette bestemmes i alminnelighet av den behandlende lege som kjenner pasientens tilstand. Virkningsfullheten av en liten dose anvendt på et ungt barn, fremgår av følgende prøve. After the third day of treatment, the young man's appetite had clearly improved. He was able to return to work and is still receiving treatment. He no longer feels apathetic. His skin tone has improved. .As will be seen, a smaller dose was used in the treatment of the young man. It is preferred that the dose is determined according to the patient's age. In general, the older the person, the larger the dose. This is generally determined by the attending physician who knows the patient's condition. The effectiveness of a small dose applied to a young child is shown by the following sample.

Pasient EPatient E

Et ungt barn på 9 år (en gutt) ble diagnostisert å ha leukemi. A young child of 9 years (a boy) was diagnosed to have leukemia.

Barnet var blekt, apatisk og viste appetittap. Den behandlende lege foreskrev en dose av preparat (1) bestående av å tilsette en dråpe derav til ca. 100 ml vann som gutten tok en gang før hvert måltid daglig. En markert forbedring ble iakttatt efter den femte behandlings-dag.. Under en behandlingstid på to måneder vokste gutten 5 cm og viste en vektøkning på 356 kg. The child was pale, apathetic and showed loss of appetite. The attending physician prescribed a dose of preparation (1) consisting of adding one drop of it to approx. 100 ml of water which the boy took once before each meal daily. A marked improvement was observed after the fifth treatment day. During a treatment period of two months, the boy grew 5 cm and showed a weight gain of 356 kg.

Behandlingene ble stanset efter 2 måneder. Gutten går på skole The treatments were stopped after 2 months. The boy goes to school

og er fremdeles under observasjon.and is still under observation.

Som det fremgår av de foregående sykehistorier, er preparatene ifølge oppfinnelsen virkningsfulle ved behandling av cancerbærende verter, særlig ved behandling av mennesker, ved anvendelse av en liten, men effektiv mengde av preparatet. Forsøk inntil dato har ikke vist noen vesentlig grad av skadelig giftighet av det nevnte preparat. As can be seen from the preceding case histories, the preparations according to the invention are effective in the treatment of cancer-bearing hosts, particularly in the treatment of humans, using a small but effective amount of the preparation. Tests to date have not shown any significant degree of harmful toxicity of the aforementioned preparation.

(Forbindelsen "friedelari-3-on" er også kjent i litteraturen som•"friedooleanan-3-on".) (The compound "friedelari-3-on" is also known in the literature as•"friedooleanan-3-on".)

Ved således å arbeide innen preparatområdene angitt ovenfor, kan doseraengder foreskrives som er tå],bare av den cancerbærende verts system. En liten, men effektiv mengde kan-, når den foreskrives for en pasient, variere fra en dråpe av oppløsningen opptil 1.5 dråper eller mere, tilsatt til en oralt konsumerbar mengde vann, idet mengden av droge bestemmes av den behandlende lege som kjenner tilfellet. Det foretrekkes ved fortynning av ethanolpreparatet i vann for oral anvendelse, at det endelige ethanolinnhold av oppløsningen ikke over-stiger 5 vekt%. I alminnelighet er det under 2% eller under 1%. Fortrinnsvis gjelder at jo yngre pasienten er, desto lavere er dose-mengden innen det ovenfor angitte område, idet 1 til 5 dråper i vann administreres oralt til en ung pasient minst én gang om dagen, og fortrinnsvis minst én gang før hvert måltid daglig, inntil det er fastslått at pasientens tilstand har forbedret seg tydelig. By thus working within the preparation ranges indicated above, dosage amounts can be prescribed which are tolerated only by the cancer-bearing host's system. A small but effective amount, when prescribed for a patient, can vary from one drop of the solution up to 1.5 drops or more, added to an orally consumable amount of water, the amount of the drug being determined by the attending physician familiar with the case. It is preferred when diluting the ethanol preparation in water for oral use that the final ethanol content of the solution does not exceed 5% by weight. In general, it is below 2% or below 1%. Preferably, the younger the patient, the lower the dose within the range indicated above, 1 to 5 drops in water being administered orally to a young patient at least once a day, and preferably at least once before each meal daily, until it has been established that the patient's condition has clearly improved.

Claims

Method for inhibiting the growth of cancer in cancer-bearing hosts, characterized in that it comprises; is the oral administration of a solution containing a small, nine effective amount of friedelan-3-one dissolved in a physiologically acceptable solution, the solution being administered in dose amounts by diluting a predetermined portion of the solution in water sufficient to be taken orally daily .

2. Method according to claim 1,

characterized in that the solution is ethanol containing a small but effective amount of each of friedelan-3-one,

chlorophyll and phenolic resin.

3. Method according to claim 1,

characterized in that the solution contains 0.01 r 0.4% by weight of friedelan-3-one dissolved in ethanol, the solution being administered in doses of 1 - 15 drops added to water sufficient to be taken orally by a patient at least "once per „ day under treatment.

4"Procedure according to claim 3"

characterized by the fact that a hano loppi øsnin.gen. contains 0.04% by weight of friedelan-3-one.

5- Method for inhibiting the growth of cancer in humans, characterized by oral administration of a solution containing 0.01 - 0.4 wt% friedelan-3-one, 0.006 - 0.12 wt% chlorophyll and 0.6 - 3.7% by weight phenolic. resin dissolved, in ethanol, the solution being administered in dosage amounts of from 1 to 15 drops added to water sufficient to be taken orally by at least one patient. once daily during treatment.

6. Procedure according to claim 5/

characterized in that the ethanol solvent contains 0.04% by weight of friedelan-3-one, 0.02% by weight of chlorophyll and 1.65% by weight of phenolic resin.

7- Method for inhibiting the growth of cancer in humans, characterized by oral administration of a solution containing 0.03339 friedelan-3-one, 0.0166 g chlorophyll and 1.3326 g phenolic resin dissolved per 100 ml of ethanol. the solution being administered in dosage amounts varying from 1 to 15 drops added to water sufficient to be taken orally by a patient at least once a day during treatment.

g. Pharmaceutical preparation for use in inhibiting the growth of cancer in humans, characterized in that it comprises an ethanol solution containing 0.01 - 0.4% by weight of friedelan-3-one, the preparation being administered orally by diluting a predetermined portion thereof in water sufficient to be taken orally by the patient.

9. Pharmaceutical preparation according to claim 8,

characterized in that the ethanol solution contains 0.04% by weight of friedelan~3 -one.

10. Pharmaceutical preparation for use in inhibiting the growth of cancer in humans, characterized in that it comprises an ethanol solution containing 0.01 - 0.4% by weight of friedelan-3-one, 0.006 - 0.12% by weight of chlorophyll and 0.6 - 3.7% by weight phenolic resin, the solution being administered orally by adding 1-15 drops thereof to water sufficient to be taken orally by a patient at least once a day during treatment.

11. Pharmaceutical preparation according to claim 10,

characterized in that the ethanol solution contains 0.04% by weight of friedelan-3-one, 0.02% by weight of chlorophyll and 1.65% by weight of phenolic resin.

12. Pharmaceutical preparation for use in inhibiting the growth of cancer in humans, characterized in that it comprises an ethanolic solution containing 0.0333 g of friedelan-3-one, 0.0166 g of chlorophyll and 1.3326 g of phenolic resin per 100 ml solution, the solution being administered orally by adding 1 - 15 drops thereof to water sufficient to be taken orally by a patient at least once a day during treatment.

13» .. Procedure for the production of a pharmaceutical preparation for use in the treatment of cancer,

characterized woe. d that a small but effective amount of friedelan-3-one is dissolved in a physiologically acceptable solution, as

the solution is administered in dosage amounts to a patient by diluting a predetermined portion of the solution in water sufficient to be taken orally.

14. Method according to claim 13,

characterized in that the small but effective amount of friedelan-3-one dissolved in the solution is from 0.01 - 0.4% by weight, and the solution is ethanol.

15- Procedure for the manufacture of a pharmaceutical preparation for use in the treatment of cancer,

characterized in that it comprises dissolving a small but effective amount of each of friedelan-3-one, chlorophyll and phenolic resin in a physiologically acceptable solution, the solution being administered in dosage amounts to a patient by diluting a predetermined portion of the solution in water sufficient to be taken orally.

l6. Procedure according to claim 1.5,

characterized in that the preparation is prepared by dissolving 0.01 - 0.4% by weight of friedelan-3-one, 0.006 - 0.12% by weight of chlorophyll and 0.6 - 3.7% by weight of phenolic resin in ethanol.